Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

As of September 30, 2021, the amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	September 30, 2021
	Valuation									Balance Sheet Classification
(In thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value		Current Assets		Noncurrent Assets
Commercial paper and corporate bonds	$	9,718	$	2	$	(1	)	$	9,719	$	7,717	$	2,002
Total	$	9,718	$	2	$	(1	)	$	9,719	$	7,717	$	2,002

Components of Inventories

Inventories consisted of the following components:

	September 30,
(In thousands)	2022		2021
Raw materials	$	6,102	$	4,165
Work-in process		1,595		1,295
Finished products		4,122		1,300
Total	$	11,819	$	6,760

Summary of Prepaids and Other Current Assets

Prepaids and other current assets consisted of the following:

	September 30,
(In thousands)	2022		2021
Prepaid expenses	$	2,570	$	1,712
Irish research and development credits receivable		753		1,164
CARES Act employee retention credit receivable		3,441		3,577
Prepaids and other	$	6,764	$	6,453

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components:

	Useful Life	September 30,
(Dollars in thousands)	(Years)	2022			2021
Land	N/A	$	4,409		$	4,419
Laboratory fixtures and equipment	3 to 10		28,810			29,482
Buildings and improvements	3 to 20		26,373			26,573
Leasehold improvements	5 to 10		6,499			6,499
Office furniture and equipment	3 to 10		9,205			8,713
Construction-in-progress			3,175			2,120
Less: Accumulated depreciation			(51,323	)		(47,716	)
Property and equipment, net		$	27,148		$	30,090

Schedule of Intangible Assets

Intangible assets consisted of the following:

	September 30, 2022
(Dollars in thousands)	Weighted Average Original Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships	8.9	$	11,354	$	(8,827	)	$	2,527
Developed technology	11.9		31,943		(7,994	)		23,949
Patents and other	14.1		3,551		(2,462	)		1,089
Total definite-lived intangible assets			46,848		(19,283	)		27,565
Unamortized intangible assets:
Trademarks and trade names			580		—			580
Total intangible assets		$	47,428	$	(19,283	)	$	28,145

	September 30, 2021
(Dollars in thousands)	Weighted Average Original Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships	8.9	$	13,216	$	(8,878	)	$	4,338
Developed technology	11.9		36,531		(5,652	)		30,879
Patents and other	14.1		3,551		(2,294	)		1,257
Total definite-lived intangible assets			53,298		(16,824	)		36,474
Unamortized intangible assets:
Trademarks and trade names			580		—			580
Total intangible assets		$	53,878	$	(16,824	)	$	37,054

Estimated Amortization Expense

Based on the intangible assets in service as of September 30, 2022, estimated amortization expense for future fiscal years is as follows:

(In thousands)
2023	$	3,549
2024		3,471
2025		3,439
2026		2,618
2027		2,384
Thereafter		12,104
Definite-lived intangible assets	$	27,565

Schedule of Carrying Amount of Goodwill By Reportable Segment

Changes in the carrying amount of goodwill by segment were as follows:

(In thousands)	In Vitro Diagnostics		Medical Device			Total
Goodwill as of September 30, 2020	$	8,010	$	19,175		$	27,185
Acquisition of Vetex Medical Limited		—		19,089			19,089
Foreign currency translation adjustment		—		(668	)		(668	)
Goodwill as of September 30, 2021		8,010		37,596			45,606
Foreign currency translation adjustment		—		(5,173	)		(5,173	)
Measurement period adjustments (1)		—		277			277
Goodwill as of September 30, 2022	$	8,010	$	32,700		$	40,710

(1)In fiscal 2022, measurement period adjustments were recorded to finalize the allocation of purchase consideration for the fiscal 2021 Vetex acquisition (Note 12).

Summary of Other Noncurrent Assets

Other noncurrent assets consisted of the following:

	September 30,
(In thousands)	2022		2021
Operating lease right-of-use assets	$	3,633	$	2,435
Other		1,136		1,283
Other assets, noncurrent	$	4,769	$	3,718

Schedule of Accrued Other Liabilities

Accrued other liabilities consisted of the following:

	September 30,
(In thousands)	2022		2021
Accrued professional fees	$	279	$	489
Accrued clinical study expense		1,425		1,667
Accrued purchases		1,655		1,195
Acquisition of in-process research and development (1)		981		494
Operating lease liability, current portion		963		518
Other		551		542
Total accrued other liabilities	$	5,854	$	4,905

(1)Acquisition of in-process research and development consists of the present value of guaranteed payments to be made (current portion) in connection with an asset acquisition in fiscal 2018 (Note 11).

Schedule of Other Long-term Liabilities

Other long-term liabilities consisted of the following:

	September 30,
(In thousands)	2022		2021
Deferred consideration (1)	$	4,260	$	5,106
Contingent consideration (2)		829		817
Unrecognized tax benefits (3)		1,841		2,538
Operating lease liabilities (4)		3,843		3,188
Other long-term liabilities	$	10,773	$	11,649

(1)Deferred consideration consisted primarily of the present value of guaranteed payments to be made in connection with the fiscal 2021 Vetex acquisition (Note 12) and with an asset acquisition in fiscal 2019 (Note 11).

(2)Contingent consideration consisted of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 5 and Note 12).

(3)Unrecognized tax benefits (Note 9) included accrued interest and penalties, if applicable.

(4)Operating lease liabilities consisted of the non-current portion of the net present value of future minimum lease payments, reduced by the discounted value of leasehold improvement incentives paid or payable to the Company.

Schedule of Operating Lease Maturities

As of September 30, 2022, operating lease maturities were as follows:

(In thousands)
2023	$	1,172
2024		1,210
2025		1,214
2026		1,132
2027		1,135
Thereafter		575
Total expected operating lease payments		6,438
Less: Imputed interest		(1,632	)
Total operating lease liabilities	$	4,806

Denominator for Computation of Diluted Weighted Average Shares Outstanding

The following table presents the denominator for the computation of diluted weighted average shares outstanding:

	Fiscal Year
(In thousands)	2022		2021		2020
Basic weighted average shares outstanding		13,916		13,765		13,552
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units		—		224		260
Diluted weighted average shares outstanding		13,916		13,989		13,812